KOSDAQElectrical Equipment302550

Remed

₩2,615▲ 0.97%2026-11-18 close
Market Cap
₩79.2B
Turnover
₩100M
Volume
50K
Shares out.
30.3M
PER
35.8×
PBR
2.0×
EPS
₩70
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Quarterly profit recovers; dilution and annual base are the key variables

Quarterly revenue and operating profit have risen together in 2026, but net profit attributable to controlling shareholders has fallen for two straight quarters since its 1Q 2026 peak, and FY2025 results were well below FY2024.

  1. 1

    Revenue has grown for four consecutive quarters from 3Q 2025 to 3Q 2026, and operating profit has risen for three consecutive quarters since its 4Q 2025 low.

  2. 2

    Net profit attributable to controlling shareholders peaked at KRW 1.12 billion in 1Q 2026 and then declined in 2Q and 3Q, diverging from the operating profit trend.

  3. 3

    FY2025 operating profit was KRW 726 million, down 35.3% year on year, and net profit attributable to controlling shareholders was KRW 526 million, down 92.7%.

  4. 4

    A KRW 10 billion convertible bond issuance and a treasury share cancellation were both disclosed in October 2026, making share count changes and the start of conversion rights in 2H 2027 key items to track.

  5. 5

    Growth in the US market and the aesthetics business remain at the outlook stage and need to show up in quarterly results from 2027 onward.

02

Business structure

Remed is an electroceutical company that develops and manufactures non-invasive neuromodulation treatment devices. Founded in 2003, the company makes devices used in psychiatry, neurology and rehabilitation medicine, according to a 2021 technical analysis report.

Its core neurorehabilitation and chronic pain segments drove revenue growth, which Rapportian cited as the main driver of profit improvement in its report on the first three quarters of 2026.

The chronic pain business is expanding on higher unit prices from upgraded products and a US FDA authorization, according to FnGuide's business summary. The neurorehabilitation business is also expected to lift sales following its FDA authorization.

The company entered the aesthetics (AES) business in earnest in 2025, applying technology proven in its existing pain management (PMS) devices to beauty treatments.

Radiofrequency (RF) and high-intensity focused ultrasound (HIFU) medical devices were effectively cleared as of a 2025 report, and the company is also preparing a shockwave-based lifting device.

Management says its products have an edge over competitors in side-effect profiles, but several energy-based devices compete in the lifting market.

The export structure is heavily tilted overseas: as of a March 2025 report, exports accounted for more than 80% of existing device sales, with expansion centered on Asian markets such as Hong Kong and Japan.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.8B₩300M4.7%
2025Q4₩6.7B₩51,350,2780.8%
2026Q1₩7.2B₩700M9.5%
2026Q2₩7.4B₩900M12.8%
2026Q3₩7.7B₩1.6B21.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩21.4B₩1.7B₩4B7.8%13.4%160.4%
2023₩18.5B-₩2.9B₩800M−15.4%2.6%78.8%
2024₩25.6B₩1.1B₩7.2B4.4%17.8%46.7%
2025₩24.5B₩700M₩500M3.0%1.3%36.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Annual revenue fell from KRW 21.4 billion in 2022 to KRW 18.5 billion in 2023 (down 13.2% year on year), rose to KRW 25.6 billion in 2024 (up 37.9%), and was KRW 24.5 billion in 2025 (down 4.1%). Among 2022 to 2025, 2024 was the largest year and 2023 the smallest.

Operating profit went from KRW 1.66 billion in 2022 to an operating loss of KRW 2.86 billion in 2023, a swing into loss, before returning to operating profit of KRW 1.12 billion in 2024. FY2025 operating profit was KRW 726 million, down 35.3% year on year.

The operating margin moved from 7.8% in 2022 to -15.4% in 2023, 4.4% in 2024 and 3.0% in 2025. Net profit attributable to controlling shareholders was KRW 4 billion in 2022, KRW 797 million in 2023 (down 80.1%), KRW 7.17 billion in 2024 (up 799.7%), and KRW 526 million in 2025 (down 92.7%).

Among 2022 to 2025, 2024 was the largest year and 2025 the smallest. Net income including non-controlling interests went from KRW 7.38 billion in 2024 to a net loss of KRW 35.47 million in 2025, a different figure from profit attributable to controlling shareholders.

Quarterly revenue rose from KRW 5.81 billion in 3Q 2025 to KRW 6.7 billion in 4Q 2025 (up 15.2% quarter on quarter), KRW 7.18 billion in 1Q 2026 and KRW 7.37 billion in 2Q 2026, reaching KRW 7.67 billion in 3Q 2026 (up 31.9% year on year). That is four consecutive quarters of growth.

Operating profit bottomed at KRW 51.35 million in 4Q 2025 (down 81.2% quarter on quarter), then rose to KRW 684 million in 1Q 2026, KRW 945 million in 2Q and KRW 1.62 billion in 3Q, three consecutive quarters of increases.

Net profit attributable to controlling shareholders swung from a KRW 211 million loss in 4Q 2025 to KRW 1.12 billion in 1Q 2026, then fell to KRW 701 million in 2Q and KRW 510 million in 3Q, two consecutive quarterly declines.

The last four quarters total KRW 2.12 billion of profit attributable to controlling shareholders. According to Rapportian, cumulative consolidated operating profit for the first three quarters of 2026 was KRW 3.25 billion, and the separate-basis operating margin came close to 20%.

Where operating profit rose while profit attributable to controlling shareholders fell, the reasons become visible only when non-operating items and income tax are examined alongside.

05

Industry analysis

Remed falls under the power equipment sector in the Korea Exchange classification, but its actual end market is hospitals and aesthetic treatment clinics.

Companies grouped in the same sector, such as LS ELECTRIC and Hyosung Heavy Industries, generally tie their earnings to power infrastructure investment, whereas Remed's demand follows treatment device and aesthetic equipment purchases.

For that reason, sector average metrics alone make it hard to read the direction of Remed's earnings. On the treatment side, neurorehabilitation and chronic pain devices are growing overseas revenue on the basis of US FDA authorization.

Rapportian's report expects US revenue growth to take hold from next year, with European expansion and Japanese sales growth also becoming visible. On the aesthetics side, several companies compete with energy-based devices using radiofrequency, ultrasound and shockwave technologies.

The company emphasizes its differentiation in side-effect profiles against competing products. A 2021 report said clinical trials were under way to apply TMS to psychiatric conditions beyond depression.

Accordingly, how quickly indication expansion converts into revenue will determine where Remed stands within its market.

06

Outlook

The outlook from the company and press reports rests on three points. First, according to a Rapportian report dated November 12, 2026, US market revenue growth is expected to become substantial starting next year.

Second, on the aesthetics side, lifting devices such as the HIFU-based Cleo V1 and shockwave-based Cleo LiftOn were introduced in 2025 as products in preparation, and whether a wider product lineup converts into revenue is the point to watch. Third, the capital structure is a variable.

The company issued a KRW 10 billion convertible bond to LF Investment in October 2026 and, in the same period, disclosed the cancellation of 701,519 treasury shares worth about KRW 2 billion. Reports say conversion rights on the bonds start in 2H 2027.

The company said it chose cancellation to prevent dilution of existing shareholders' stake value. Based on last year's timing, the 4Q 2026 and full-year preliminary results are likely to come around late February 2027.

The FY2026 annual report must be filed by the end of March 2027, when confirmed full-year operating margin and net profit attributable to controlling shareholders will be available.

07

Valuation

PER
35.8×
PBR
2.0×
ROE
5.4%
EPS
₩70
BPS
₩1,260
Dividend per share
₩0

Valuation should be read alongside the earnings trend. Profit attributable to controlling shareholders over the last four quarters totals KRW 2.12 billion, and on a quarterly basis it has declined in 2Q and 3Q 2026 after peaking in 1Q 2026.

When profit falls, the same share price implies a higher multiple of earnings, so the quarterly profit trend should be checked alongside any multiple. The price-to-book ratio sits above 1x, which means the stock trades at a premium to book value.

Total equity at end-2025 was KRW 39.5 billion, equity attributable to controlling shareholders was KRW 40.1 billion, and total liabilities were KRW 14.4 billion. Treasury share cancellation, rather than cash dividends, has been the main form of shareholder return.

Per-share metrics can change with share cancellations and bond conversions, so they should be rechecked whenever disclosures are updated. Losses and profits alternated from 2022 to 2025, but recent quarters show continued operating profit, so the basis for reading valuation has shifted toward earnings recovery.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Revenue and operating profit rising together

Revenue has grown for four consecutive quarters through 3Q 2026, and 3Q 2026 revenue was up 31.9% year on year. Operating profit has risen for three straight quarters since the 4Q 2025 low, reaching KRW 1.62 billion in 3Q 2026. Both measures improving together shows margin recovery in the quarterly results.

Cumulative profitability gains and overseas growth outlook

According to Rapportian, the separate-basis operating margin for the first three quarters of 2026 came close to 20%. The same report expects US revenue growth to become significant from next year, with Europe and Japan also rising.

With a heavily overseas sales mix, expanding revenue from FDA-authorized products could be the next step in earnings improvement.

New aesthetics business and shareholder return moves

A 2025 report said radiofrequency and HIFU device approvals were effectively secured, bringing the aesthetics business into full operation. In October 2026 the company disclosed plans to cancel 701,519 treasury shares worth about KRW 2 billion. If aesthetics revenue builds up, business diversification could follow.

09

Bear factors

Volatility in annual results

In 2023 the company swung to an operating loss of KRW 2.86 billion, and in 2025 operating profit fell 35.3% year on year. Profit attributable to controlling shareholders dropped 92.7% to KRW 526 million in 2025, and net income including non-controlling interests turned to a KRW 35.47 million net loss. Quarterly improvement is continuing, but on an annual basis the earnings base has not yet proven stable.

Recent decline in profit attributable to controlling shareholders

Profit attributable to controlling shareholders fell 37.1% from KRW 1.12 billion in 1Q 2026 to KRW 701 million in 2Q, then dropped 27.2% to KRW 510 million in 3Q. Operating profit rose over the same period, which points to other items such as non-operating results or taxes. Whether operating gains keep failing to reach controlling shareholders is the bearish point to monitor.

Potential dilution from convertible bonds

A KRW 10 billion convertible bond issued to LF Investment in October 2026 was reported, with conversion rights reportedly starting in 2H 2027. The company cancelled treasury shares to ease concerns about new share supply, but actual conversions would increase the share count. The degree of dilution to existing holders will depend on conversion price and volume.

10

Risk factors

Capital dilution risk

Conversion rights on the bonds reportedly start in 2H 2027, leaving a source of future share count growth. Treasury share cancellation reduces shares outstanding, but whether it offsets the bond shares depends on conversion terms. Per-share metrics will change with cancellations and conversions and should be rechecked with each disclosure.

Overseas dependence risk

As of a March 2025 report, exports accounted for more than 80% of existing device sales. A heavily overseas sales structure makes earnings sensitive to local approvals, procurement and exchange rates. Since revenue declined in 2025, overseas demand volatility is evident, so the pace of export diversification matters.

Visibility risk of new business revenue

The aesthetics business was introduced in 2025 as a product launch stage, and its revenue contribution can so far be judged only through quarterly results. Revenue recognition timing can vary with distribution structure.

If the new business does not grow as expected, sustaining the current pace of earnings improvement could be difficult.

11

What to watch next

  1. Around late February 2027

    4Q 2026 and full-year preliminary results. Since FY2025 earnings were weak, this is where to check whether the full-year operating margin matches the quarterly trend.

  2. By end of March 2027

    Filing of the FY2026 annual report. This will confirm full-year profit attributable to controlling shareholders, the gap with net income, and the non-operating and tax items.

  3. Around mid-May 2027

    1Q 2027 results. This is where to check whether the US market revenue growth expected to become significant from next year shows up in quarterly figures.

  4. 2H 2027

    Start of conversion rights on the KRW 10 billion convertible bond. This is where to check how conversion volume and price affect share count and ownership structure.

12

Overall view

Remed's recent results show a clear quarterly recovery. Revenue has grown for four consecutive quarters, and operating profit has risen for three straight quarters since the 4Q 2025 low.

On the other hand, profit attributable to controlling shareholders has declined for two quarters since its 1Q 2026 peak, and FY2025 operating profit and profit attributable to controlling shareholders both fell sharply.

Bullish factors are the quarterly improvement, expectations for revenue from FDA-authorized products in the US, and shareholder return through treasury share cancellation.

Bearish factors are the volatility of annual results, the recent decline in profit attributable to controlling shareholders, possible dilution once bond conversions begin in 2H 2027, and heavy reliance on overseas exports. How valuation should be read depends on whether the earnings recovery continues. The next checkpoints are the FY2026 annual report, 1Q 2027 results and the start of bond conversion rights.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. newsprime.co.kr
  3. orangeboard.co.kr
  4. m.news.nate.com
  5. marketin.edaily.co.kr
  6. news.nate.com
  7. ssl.pstatic.net
  8. m.thinkpool.com
  9. news.nate.com
  10. pharm.edaily.co.kr
  11. job-post.co.kr
  12. rapportian.com
  13. bloter.net
  14. view.asiae.co.kr
  15. m.news.nate.com
  16. biotimes.co.kr
  17. news.dealsitetv.com
  18. x.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis